OGT to develop tumour profiling assay to facilitate personalised cancer treatment
Company receives £1.16m award from the UK’s Technology Strategy Board
As part of the new project, OGT will utilise its expertise in the design of high-quality, high-throughput genomic services to develop a flexible tumour profiling assay that reduces sample processing costs and turnaround times. The assay will detect mutations at informative loci, forming part of an integrated workflow that translates test results into clear clinical decisions. Such a solution would ultimately be provided as either a testing service or by the sale of an analysis ‘kit’ that could be used in-house by existing clinical laboratories. In addition, OGT will use its experience in data interpretation to adapt its powerful CytoSure Interpret Software to analyse the results provided by the new assays, making it simple to generate informative, easy-to-understand reports. James Clough, OGT’s Vice President of Clinical and Genomic Solutions, commented: “OGT has significant experience in utilising its ISO-accredited laboratories to process large numbers of samples and produce reliable results, quickly, accurately and efficiently. The new cancer profiling assay will complement OGT’s other microarray and sequencing solutions, further expanding the analytical options we provide. Such a service facility is novel in the UK and will benefit the patient, clinician and healthcare funder in terms of quality of care and cost-effectiveness.”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.